ANNOUNCEMENTS: We are pleased to inform you that the Follistatin gene transfer for inclusion-body myositis has cleared its last regulatory hurdle and recruitment of patients begins this December. The trial to be conducted at Nationwide Children’s Hospital in Columbus, OH expects to select patients in December to be enrolled, with the first patient injection to begin in January, 2012. The group at Nationwide Children’s have worked hard to begin what we hope will be helpful to patients with sIBM to improve muscle strength. TMA will keep in touch with the investigators regarding the progress of the trial. Should you have any questions about the trial or patient recruitment, please contact Xiomara Rosales-Quintero at Xiomara.Rosales-Quintero@nationwidechildrens.org.
Johns Hopkins Myositis Center
USE OF THIS SITE
All information contained within the Johns Hopkins Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.
